for people ages 40 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion
Principal Investigator
by Schafer Boeder
Photo of Schafer Boeder
Schafer Boeder



The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Official Title

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)


Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Hypoglycemic Agents Physiological Effects of Drugs Tirzepatide Incretins Glucagon-Like Peptide 1 Gastric Inhibitory Polypeptide Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Dulaglutide


You can join if…

Open to people ages 40 years and up

  • Have a diagnosis of type 2 diabetes
  • Have confirmed atherosclerotic cardiovascular disease
  • HbA1c ≥7.0% to ≤10.5%
  • Body mass index (BMI) ≥25 kilograms per meter squared (kg/m²)

You CAN'T join if...

  • Have had a major cardiovascular event within the last 60 days
  • Have type 1 diabetes mellitus
  • Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
  • Are currently planning treatment for diabetic retinopathy and/or macular edema
  • Currently planning a coronary, carotid, or peripheral artery revascularization
  • Have a history of pancreatitis
  • Have a history of ketoacidosis or hyperosmolar state/coma
  • Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement


  • UCSD Clinical & Translational Research Institute accepting new patients
    La Jolla California 92037 United States
  • Diabetes and Endocrine Associates accepting new patients
    La Mesa California 91942 United States

Lead Scientist at UCSD

  • Schafer Boeder
    Associate Physician, Medicine. Authored (or co-authored) 7 research publications.


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Phase 3
Study Type
Last Updated